原发性肝细胞癌系统化疗研究进展

Research progress of systemic chemotherapy for primary hepatocellular carcinoma

原发性肝细胞癌是我国发病率较高的恶性肿瘤,其特点为起病隐匿,发展速度快,早期诊断难度较大,确诊时大多已达晚期,可手术的病例占少数,如仅给予支持治疗则生存期较短。对于中晚期肝癌,多采用系统治疗作为姑息治疗的主要手段,用以延长患者生存期,改善生活质量。此前部分传统的细胞毒药物曾试用于原发性肝癌,但单药有效率较低,缺乏高级别的循证医学证据支持。近几年对于原发性肝癌的化疗已开展了众多临床研究,其中很多结果令人鼓舞,现重点针对肝癌的化疗研究作一综述。

Primary hepatocellular carcinoma is a malignant tumor with high incidence in China, characterized by insidious onset, rapid progress, and more difficulties in early diagnosis. Most of the patients were diagnosed with advanced stage, but only a few cases can be operated and the survival time of the patients treated with supportive treatment is shorter than that of the patients. For the middle and advanced stage of hepatocellular carcinoma, systemic treatment is often used as a main means of palliative treatment, to prolong the survival period and improve life quality of paetients. In the past, some traditional cytotoxic drugs have been on trial, which is showed with lower effective rate and a lack of high-level evidence-based medicine evidence to support its survival benefit. In recent years, many clinical studies on the chemotherapy for primary hepatocellular carcinoma have been carried out and published, many of these results are encouraging. This paper comprehensively reviewed the research achievements on chemotherapy.